OK, this paper actually has massive implications for topoisomerase drug discovery because it challenges a long-standing assumption about TOP2 poisons. Rather than simply trapping the cleavage complex (as etoposide does), the authors propose that their modified epipodophyllotoxin derivative actively dismantles the TOP2β catalytic apparatus, producing an irreversible, religation-defective complex that leads to persistent DNA double-strand breaks.
Topoisomerase II enzymes remain among the most important targets in cancer chemotherapy, yet clinically successful drugs such as etoposide are limited by drug resistance and treatment-associated toxicities. A recently published study in the International Journal of Biological Macromolecules reports a potentially important advance in TOP2 drug discovery through the characterization of a novel 4β-S-DMEP derivative that inhibits human TOP2β through an unexpected mechanism.
Using crystallography, biochemical analysis, and computational modeling, the investigators discovered that the compound induces a unique “open-state” TOP2β cleavage complex that is incapable of DNA religation. Unlike classical TOP2 poisons that primarily stabilize the cleavage complex, this agent appears to promote disruption of the catalytic phosphotyrosyl linkage itself, effectively dismantling the enzyme’s religation machinery and driving the formation of persistent DNA double-strand breaks.
The study provides one of the clearest structural views yet of how rational modifications to the epipodophyllotoxin scaffold can dramatically alter topoisomerase biology. Importantly, the work suggests a path toward next-generation TOP2-targeted therapeutics designed to overcome resistance mechanisms that limit conventional agents.
At TopoGEN, we recognize that breakthroughs such as these depend upon access to high-quality topoisomerases, validated DNA substrates, and robust mechanistic assay systems capable of distinguishing catalytic inhibition from cleavage-complex formation and enzyme poisoning. As researchers continue to explore new strategies for targeting TOP2α and TOP2β, mechanistic studies of enzyme function will remain essential for advancing safer and more effective anti-cancer therapies.
For decades, TopoGEN has supported the global scientific community with validated topoisomerases, DNA substrates, antibodies, and drug discovery assay platforms that help transform mechanistic insights into therapeutic innovation.
The phrase “dismantling the religation machinery” is new and very appropriate because it captures what makes this paper different from dozens of routine TOP2 poison studies. That’s the novelty reviewers and medicinal chemists will remember.
Malik Sadaf Ali, Wei Zhao, Hong-Mei Li, Jing-Yuan Cong, Ya-Jie Tang,
Thiadiazole-4β-sulfur-demethylepipodophyllotoxin traps human topoisomerase IIβ by distorting DNA and disrupting the tyrosyl-DNA linkage,
International Journal of Biological Macromolecules, Volume 370, 2026, 152972, ISSN 0141-8130
https://doi.org/10.1016/j.ijbiomac.2026.152972.
https://www.sciencedirect.com/science/article/pii/S0141813026028990